BP-294 (Ste Civile Bioprojet).
BP-294 (a prodrug of R-alpha-methylhistamine) is a histamine-H(3) agonist under development by Bioprojet, which is currently in phase II clinical trials as a potential treatment for asthma [219798].
Fozard
J R
JR
Research Department, Novartis Pharma AG, Building 386/1035, Postfach, CH-4002 Basel, Switzerland. john_r.fozard@pharma.novartis.com